Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Myeloproliferative Neoplasms

Nicolaus Kröger  1 , Donal P. McLornan  2 , Yves Chalandon  3
Anna Sureda  1 , Selim Corbacioglu  2 , Raffaella Greco  3 , Nicolaus Kröger  4 , Enric Carreras  5
, editors.
In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 77.
.
Affiliations
Review

Myeloproliferative Neoplasms

Nicolaus Kröger et al.

Excerpt

Polycythemia vera (PV) and essential thrombocythemia (ET) have a favorable outcome without need for allo-HCT unless the disease has progressed to post-ET/PV myelofibrosis or secondary AML (Lussana et al. 2014).

PubMed Disclaimer

References

    1. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53–66. - PubMed
    1. Byrne JL, Beshti H, Clark D, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol. 2000;108:430–3. - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901. - PubMed
    1. Chalandon Y, Passweg JR, Schmid C, et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant. 2010;45:558–64. - PubMed
    1. Chalandon Y, Iacobelli S, Hoek J et al. Use of first or second generation TKI for CML after allogeneic hematopoietic stem cell transplantation: a study by the CMWP of the EBMT. In: EBMT annual meeting, Marseille, France, 2017.